3. ACADIA Pharmaceuticals, Inc. ( ACAD): Focuses on drug discovery and clinical development of novel treatments for central nervous system disorders.
Market cap at $1.755B, most recent closing price at $20.89.
Over the last six months, insiders were net buyers of 3,964,834 shares, which represents about 8.04% of the company's 49.34M share float.
ACADIA Pharmaceuticals has returned -23.80% since October 7 th, falling considerably behind several industry peers including Gilead Sciences and Amgen, which returned 9.05% and 2.82% during the same time period.In the pipeline: During the company's third quarter earnings call, CEO Uli Hacksell stated that ACADIA is on track to submit a new drug application for its pimavanserin medication - specifically for the treatment of Parkinson's disease psychosis (PDP) – to the FDA near the end of 2014. Pimavanserin is also in clinical trials for the treatment of schizophrenia and Alzheimer's disease psychosis; ACADIA completed its Phase 2 trial for schizophrenia last year and will commence the Phase 2 trial for Alzheimer's disease psychosis (ADP) this month. Currently no drugs have been approved for the treatment of either PDP or ADP in the US. ( List compiled by Mary-Lynn Cesar, a Kapitall Writer. Insider data sourced from Yahoo! Finance. Analyst ratings data sourced from Zacks Investment Research. All other data sourced from Finviz)